JP2022058682A5 - - Google Patents

Download PDF

Info

Publication number
JP2022058682A5
JP2022058682A5 JP2022007043A JP2022007043A JP2022058682A5 JP 2022058682 A5 JP2022058682 A5 JP 2022058682A5 JP 2022007043 A JP2022007043 A JP 2022007043A JP 2022007043 A JP2022007043 A JP 2022007043A JP 2022058682 A5 JP2022058682 A5 JP 2022058682A5
Authority
JP
Japan
Prior art keywords
synergistic combination
gram
composition
amino acid
antibiotics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022007043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022058682A (ja
Filing date
Publication date
Priority claimed from JP2019221319A external-priority patent/JP2020054370A/ja
Application filed filed Critical
Publication of JP2022058682A publication Critical patent/JP2022058682A/ja
Publication of JP2022058682A5 publication Critical patent/JP2022058682A5/ja
Pending legal-status Critical Current

Links

JP2022007043A 2012-05-09 2022-01-20 グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ Pending JP2022058682A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261644944P 2012-05-09 2012-05-09
US61/644,944 2012-05-09
US201261737239P 2012-12-14 2012-12-14
US61/737,239 2012-12-14
JP2019221319A JP2020054370A (ja) 2012-05-09 2019-12-06 グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019221319A Division JP2020054370A (ja) 2012-05-09 2019-12-06 グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ

Publications (2)

Publication Number Publication Date
JP2022058682A JP2022058682A (ja) 2022-04-12
JP2022058682A5 true JP2022058682A5 (enrdf_load_stackoverflow) 2023-01-04

Family

ID=49551273

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015511698A Expired - Fee Related JP6608697B2 (ja) 2012-05-09 2013-05-09 グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ
JP2018086685A Withdrawn JP2018138045A (ja) 2012-05-09 2018-04-27 グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ
JP2019221319A Pending JP2020054370A (ja) 2012-05-09 2019-12-06 グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ
JP2022007043A Pending JP2022058682A (ja) 2012-05-09 2022-01-20 グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2015511698A Expired - Fee Related JP6608697B2 (ja) 2012-05-09 2013-05-09 グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ
JP2018086685A Withdrawn JP2018138045A (ja) 2012-05-09 2018-04-27 グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ
JP2019221319A Pending JP2020054370A (ja) 2012-05-09 2019-12-06 グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ

Country Status (16)

Country Link
US (5) US10813983B2 (enrdf_load_stackoverflow)
EP (2) EP2849782B1 (enrdf_load_stackoverflow)
JP (4) JP6608697B2 (enrdf_load_stackoverflow)
KR (3) KR20230113404A (enrdf_load_stackoverflow)
CN (1) CN104736172A (enrdf_load_stackoverflow)
AU (3) AU2013259512B2 (enrdf_load_stackoverflow)
BR (1) BR112014027842A2 (enrdf_load_stackoverflow)
CA (1) CA2872902A1 (enrdf_load_stackoverflow)
DK (1) DK2849782T3 (enrdf_load_stackoverflow)
ES (1) ES2784136T3 (enrdf_load_stackoverflow)
HK (1) HK1211484A1 (enrdf_load_stackoverflow)
IL (3) IL308477A (enrdf_load_stackoverflow)
IN (1) IN2014MN02437A (enrdf_load_stackoverflow)
MX (2) MX389127B (enrdf_load_stackoverflow)
RU (2) RU2018121290A (enrdf_load_stackoverflow)
WO (1) WO2013170015A1 (enrdf_load_stackoverflow)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX369056B (es) 2012-05-09 2019-10-28 Contrafect Corp Prevención, interrupción y tratamiento de biopelículas con lisina de bacteriófago.
RU2018121290A (ru) 2012-05-09 2019-03-06 Контрафект Корпорейшн Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий
RU2725809C2 (ru) 2014-06-26 2020-07-06 Дзе Рокфеллер Юниверсити Лизины ацинетобактеров
AU2016231141B2 (en) * 2015-03-12 2022-03-03 Micreos Human Health B.V. Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection
WO2017049242A2 (en) * 2015-09-17 2017-03-23 Contrafect Corporation Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
US10851401B2 (en) * 2016-05-12 2020-12-01 Contrafect Corporation Broth microdilution method for evaluating and determining minimal inhibitory concentration of antibacterial polypeptides
DK3641753T3 (da) 2017-06-19 2022-12-12 Univ Syddansk Bacitracin og/eller daptomycin kombineret med cannabidiol til behandling af bakterieinfektioner
EP3651739A4 (en) * 2017-07-10 2021-04-07 Contrafect Corporation BLOOD COMPONENT POTENTIALIZATION OF LYTIC PROTEIN ANTIBACTERIAL ACTIVITY AND RELATED METHODS AND USES
JP2021513865A (ja) * 2018-02-26 2021-06-03 コントラフェクト コーポレイション 修飾ＰｌｙＳｓ２溶解素及びその使用
WO2019246552A1 (en) * 2018-06-22 2019-12-26 Contrafect Corporation Lysins and derivatives thereof resensitize staphylococcus aureus and gram-positive bacteria to antibiotics
CN109668873B (zh) * 2018-12-05 2021-03-16 山东恒业生物技术有限公司 一种活载体疫苗活性检测装置及其使用方法
BR112021015321A2 (pt) * 2019-02-05 2021-10-05 Elanco Us Inc. Plataforma de dispensação viva, cassete de expressão, sequência de ácido nucleico, biomolécula, atividade anti-infecciosa, anticorpo, e, método para reduzir a colonização de um animal por uma bactéria patogênica
MX2021011469A (es) * 2019-03-22 2021-10-22 Contrafect Corp Combinacion de lisina(s) y antibiotico(s) para tratar o prevenir endocarditis infecciosa debida a bacterias gram-positivas.
US20220193186A1 (en) * 2019-04-11 2022-06-23 Contrafect Corporation Method of treating and preventing bone and joint infections
US20230105108A1 (en) * 2019-12-19 2023-04-06 Georgia State University Research Foundation, Inc. Compounds for the treatment of bacterial infections and potentiation of antibiotics
AU2021275048A1 (en) * 2020-05-19 2023-02-02 Contrafect Corporation Modified PlySs2 lysins and antibiotic combinations for use against Gram-positive bacteria
RU2755817C1 (ru) * 2020-07-22 2021-09-21 Федеральное Государственное бюджетное научное учреждение "Федеральный научный центр биологических систем и агротехнологий российской академии наук" Способ снижения грамположительной микрофлоры в кишечнике птицы
KR102528412B1 (ko) * 2020-09-08 2023-05-04 클립스비엔씨 주식회사 신규한 포도상구균 감염 질환의 예방 또는 치료용 조성물
WO2022261360A1 (en) * 2021-06-09 2022-12-15 Contrafect Corporation Plyss2 lysins and variants thereof for use against multidrug resistant gram-positive bacteria
CN115105491B (zh) * 2022-07-08 2023-12-22 东北农业大学 丝氨酸在制备抑制猪链球菌药物中的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988002781A1 (en) 1986-10-08 1988-04-21 David Bernstein Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci
CA1315229C (en) 1987-06-10 1993-03-30 Patrick J. Baker Chromatographic purification process
CA2251724A1 (en) * 1996-04-15 1997-10-23 Paul Averback Compositions containing bacteriophages and methods of using bacteriophages to treat infections
US5997862A (en) 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections
US6248324B1 (en) 1997-10-31 2001-06-19 Vincent Fischetti Bacterial phage associated lysing enzymes for treating dermatological infections
US6264945B1 (en) 1997-10-31 2001-07-24 Vincent A Fischetti Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US6254866B1 (en) 1997-10-31 2001-07-03 New Horizons Diagnostics Corporation Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract
US20060292135A1 (en) 1997-10-31 2006-12-28 Lawrence Loomis Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl
AU2876799A (en) 1999-02-25 2000-09-14 New Horizons Diagnostics, Inc. A means for the prophylactic and therapeutic treatment of streptococcal infections
US6056955A (en) 1999-09-14 2000-05-02 Fischetti; Vincent Topical treatment of streptococcal infections
US6444813B2 (en) 2000-02-02 2002-09-03 Pharmacia & Upjohn Company Linezolid-crystal form II
EP1501925A4 (en) 2002-05-17 2006-10-25 New Horizons Diagnostics Corp IDENTIFICATION OF A LYTIC ENZYME ASSOCIATED WITH A PHAGE TO DETECT AND ELIMINATE RAPIDLY AND SPECIFICALLY BACILLUS ANTHRACIS
US7569223B2 (en) 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
WO2005089527A2 (en) 2004-03-24 2005-09-29 The Rockefeller University Lytic enzymes and spore surface antigen for detection and treatment of bacillus anthracis bacteria and spores
US8389469B2 (en) 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
EP1917355B1 (en) 2005-08-24 2010-12-08 The Rockefeller University Ply-gbs mutant lysins
US20090053149A1 (en) 2007-08-24 2009-02-26 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Surfactant-based antimicrobial solution for inhalation
US8840900B2 (en) * 2008-07-03 2014-09-23 The Rockefeller University Chimeric bacteriophage lysin with activity against Staphylococci bacteria
KR101016918B1 (ko) 2009-01-08 2011-02-25 주식회사 인트론바이오테크놀로지 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질
EP2539446B1 (en) 2010-01-25 2017-11-01 Alere Scarborough Inc. A25 bacteriophage lysin
US20120271770A1 (en) * 2011-04-20 2012-10-25 Visa International Service Association Managing electronic tokens in a transaction processing system
EP3252155A1 (en) 2011-04-21 2017-12-06 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
US20140179594A1 (en) 2011-04-21 2014-06-26 The Rockefeller University Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock
WO2012145693A1 (en) 2011-04-22 2012-10-26 Rks Design, Inc. Instrument retention assembly
US20140120074A1 (en) 2011-04-27 2014-05-01 Lysando Ag Antimicrobial agents
RU2018121290A (ru) 2012-05-09 2019-03-06 Контрафект Корпорейшн Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий
MX369056B (es) * 2012-05-09 2019-10-28 Contrafect Corp Prevención, interrupción y tratamiento de biopelículas con lisina de bacteriófago.

Similar Documents

Publication Publication Date Title
JP2022058682A5 (enrdf_load_stackoverflow)
JP2022163214A5 (enrdf_load_stackoverflow)
RU2020133461A (ru) Предотвращение, разрушение и обработка биопленки лизином бактериофага
RU2014149351A (ru) Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий
Eckmann et al. Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin
Tagg Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius
Feld Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons
Plouffe Emerging therapies for serious gram-positive bacterial infections: a focus on linezolid
RU2018107249A (ru) Применение лизина для восстановления/увеличения антибактериальной активности антибиотиков в присутствии легочного сурфактанта, который ингибирует указанные антибиотики
Finney et al. Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections
CN101175531A (zh) 包含一种抗菌药以及一种选自香芹醇、麝香草酚、丁香酚、冰片、香芹酚的活性物质的药物组合物
RU2011130278A (ru) Новые противобактериальные средства для лечения грамположительных инфекций
JP2012513467A5 (enrdf_load_stackoverflow)
Paterson Clinical experience with recently approved antibiotics
Fan et al. Antibacterial activity of the recombinant antimicrobial peptide Ib-AMP4 from Impatiens balsamina and its synergy with other antimicrobial agents against drug resistant bacteria
Chaftari et al. Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients
RU2020128276A (ru) МОДИФИЦИРОВАННЫЕ ЛИЗИНЫ PlySs2 И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
Oksuz et al. Susceptibility of clinical methicillin-resistant Staphylococci isolates to new antibiotics
RU2004118716A (ru) Лечение инфекции, вызываемой микроорганизмами
Matsukawa et al. Staphylococcus aureus bacteriuria and surgical site infections by methicillin-resistant Staphylococcus aureus
Marie et al. Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients.
RU2020127327A (ru) Патогенные бактерии
Kajihara et al. Comparative efficacies of daptomycin, vancomycin, and linezolid in experimental enterococcal peritonitis
JP2018521143A5 (enrdf_load_stackoverflow)
Bell et al. Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008)